ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Gang de crsis de cave

<< Previous

Bullboard Posts

Next >>

Comment by Alex1726on Oct 22, 2021 6:51pm

98 Views

Post# 34039642

RE:RE:Gang de crsis de cave

Les $20 M qu ils sont alle chercher c est pour payer les frais de la cotation au nasdaq et la remuneration pour les amis , avant de debuter la phase I ils vont aller collecter un autre $50 M et ce n est que le debut , vous avez ete des rats de laboratoires pour eux

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale